It’s irrelevant and I believe the reasons are given. It was not an actual “halt”, it was a partial halt. The trial is short patients who turned out to be placebo patients. Further, because if the crossover the placebo arm was not fit for purpose, hence the use of an external placebo arm. It’s all basically there, they just didn’t spell it out for you as there was no reason to do so.
Nothing is missing. And the reality is, there would be no reason to do so, and if this was BP, they’d not do so either. There was never a safety issue, there was not apparently a futility recommendation, likely because of the survival data. Had there been, that would have had to have been revealed I expect. Hence the banging and accusations and claims and complaints and even lost lawsuits (Lerner, a lawsuit lost by shorts claiming a futility recommendation, effectively and trying to get it revealed, which they lost).
The reality is that shorts have wanted and been waiting for a revelation of something that likely never happened but that they and AF speculated happened and for all of these years they have been trying to bash the doors, like hungry wolves, in to get a revelation of something that apparently never happened.
Market Data 
Markets 
AI
